MCID: LSH001
MIFTS: 66

Leishmaniasis malady

Categories: Rare diseases, Infectious diseases, Skin diseases

Aliases & Classifications for Leishmaniasis

Aliases & Descriptions for Leishmaniasis:

Name: Leishmaniasis 12 50 52 41 3 42 14 69
Post-Kala-Azar Dermal Leishmaniasis 12 69
Post-Kala-Azar Dermal Infectious Disease by Leishmaniasis 12
Post Kala-Azar Dermal Leishmaniasis 12
Leishmaniasis, Cutaneous 69
Cutaneous Leishmaniasis 50
Leishmaniasis, Visceral 69
Visceral Leishmaniasis 50
Kala-Azar 50

Classifications:



External Ids:

Disease Ontology 12 DOID:9065
ICD10 33 B55 B55.9
ICD9CM 35 085 085.9
MeSH 42 D007896
NCIt 47 C34767
UMLS 69 C0023281

Summaries for Leishmaniasis

MedlinePlus : 41 leishmaniasis is a parasitic disease spread by the bite of infected sand flies. there are several different forms of leishmaniasis. the most common are cutaneous and visceral. the cutaneous type causes skin sores. the visceral type affects internal organs such as the spleen, liver, and bone marrow. people with this form usually have fever, weight loss, and an enlarged spleen and liver. leishmaniasis is found in parts of about 88 countries. most of these countries are in the tropics and subtropics. it is possible but very unlikely that you would get this disease in the united states. but you should be aware of it if you are traveling to the middle east or parts of central america, south america, asia, africa or southern europe. treatment is with medicines that contain antimony, a type of metal, or with strong antibiotics. the best way to prevent the disease is to protect yourself from sand fly bites: stay indoors from dusk to dawn, when sand flies are the most active wear long pants and long-sleeved shirts when outside use insect repellent and bed nets as needed centers for disease control and prevention

MalaCards based summary : Leishmaniasis, also known as post-kala-azar dermal leishmaniasis, is related to hepatitis and tuberculosis, and has symptoms including arthralgia, fatigue and night sweats. An important gene associated with Leishmaniasis is IL10 (Interleukin 10), and among its related pathways/superpathways are Innate Immune System and PEDF Induced Signaling. The drugs chloroquine and Primaquine have been mentioned in the context of this disorder. Affiliated tissues include skin, liver and spleen, and related phenotypes are Increased shRNA abundance (Z-score > 2) and hematopoietic system

Disease Ontology : 12 A parasitic protozoa infectious disease that involves infection caused by protozoan parasite of the genus Leishmania, which is transmitted by the bite of sand fly (subfamily Phlebotominae).

NIH Rare Diseases : 50 leishmaniasis is a parasitic disease spread by the bite of infected sand flies. there are several different forms of leishmaniasis. the most common are cutaneous and visceral. the cutaneous type causes skin sores. the visceral type affects internal organs such as the spleen, liver and bone marrow. people with this form usually have fever, weight loss, and an enlarged spleen and liver. visceral disease can be deadly without proper treatment. leishmaniasis is found in parts of the middle east, central america, south american, asia, africa, and southern europe. most of these countries are in the tropics and subtropics. it is possible but very unlikely to get this disease in the united states. last updated: 7/6/2011

CDC : 3 Leishmaniasis is a parasitic disease that is found in parts of the tropics, subtropics, and southern Europe. It is classified as a Neglected Tropical Disease (NTD). Leishmaniasis is caused by infection with Leishmania parasites, which are spread by the bite of phlebotomine sand flies. There are several different forms of leishmaniasis in people. The most common forms are cutaneous leishmaniasis, which causes skin sores, and visceral leishmaniasis, which affects several internal organs (usually spleen, liver, and bone marrow).

Wikipedia : 71 Leishmaniasis, also spelled leishmaniosis, is a disease caused by parasites of the Leishmania type. It... more...

Related Diseases for Leishmaniasis

Diseases related to Leishmaniasis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 397)
id Related Disease Score Top Affiliating Genes
1 hepatitis 30.1 IFNG IL10 TNF
2 tuberculosis 29.7 IL10 IL1B IL4 TLR9 TNF
3 lagophthalmos 29.7 IL10 IL4 TNF
4 lymphoblastic leukemia 29.5 IL13 IL4 IL5
5 histiocytosis 29.5 IL1A IL1B TLR2 TLR4 TNF
6 pulmonary tuberculosis 29.3 IFNG IL10 IL13 IL4 IL5 TLR4
7 polyarteritis nodosa 29.3 IFNG TLR2 TLR4 TLR9
8 splenic marginal zone lymphoma 29.3 NOS2 TGFB1 TNF
9 myiasis 29.2 IFNG IL10 IL4 SLC11A1 TGFB1 TLR4
10 rheumatoid arthritis 29.1 IFNG IL10 IL1A IL1B IL4 SLC11A1
11 membranoproliferative glomerulonephritis 29.1 IL10 IL4 IL5 TLR9 TNF
12 cutaneous leishmaniasis 12.5
13 visceral leishmaniasis 12.5
14 mucocutaneous leishmaniasis 12.4
15 kala-azar 1 11.3
16 chronic rhinitis 10.8
17 myoglobinuria recurrent 10.4 IFNG IL4
18 asymptomatic neurosyphilis 10.4 IFNG IL10 IL4
19 tubular renal disease-cardiomyopathy syndrome 10.4 IL10 IL4 TNF
20 pyridoxal 5'-phosphate-dependent epilepsy 10.4 IL10 TNF
21 refractory celiac disease 10.4 IL10 TGFB1
22 autosomal dominant deafness-onychodystrophy syndrome 10.4 IFNG IL4 TNF
23 tungiasis 10.4 IFNG IL10 IL4
24 severe combined immunodeficiency, t cell-negative, b-cell/natural killer-cell positive 10.4 IFNG IL10 TNF
25 conidiobolomycosis 10.4 IL10 IL4 TNF
26 vestibule of mouth cancer 10.4 IL10 IL4 TNF
27 clostridium difficile colitis 10.3 IFNG IL4 TNF
28 cyclosporiasis 10.3 IFNG IL10 TNF
29 idiopathic hypertrophic pachymeningitis 10.3 IL10 NOS2 TNF
30 conduct disorder 10.3 IFNG IL10 TNF
31 pancreatic signet ring cell adenocarcinoma 10.3 IFNG IL10 TNF
32 distal trisomy 14q 10.3 IFNG TGFB1 TNF
33 spotted fever 10.3 TLR2 TLR4 TNF
34 oral cavity cancer 10.3 IFNG IL4 TNF
35 leukoplakia of penis 10.3 IL10 IL4 TLR2
36 aortic coarctation 10.3 TLR2 TLR4 TNF
37 hereditary alpha tryptasemia syndrome 10.3 IFNG IL10 TNF
38 discharging ear 10.3 IFNG IL10 TGFB1
39 erb-duchenne and dejerine-klumpke palsies 10.3 IFNG IL10 TNF
40 goat milk allergy 10.3 IL10 IL13 IL4
41 tarsal tunnel syndrome 10.3 IL10 IL13 TNF
42 myofibroma 10.3 IFNG IL10 IL13
43 aseptic meningitis 10.3 TLR2 TLR4 TNF
44 nystagmus, congenital motor, autosomal recessive 10.3 SLC11A1 TLR2 TNF
45 red cell phospholipid defect with hemolysis 10.3 IFNG IL4 TNF
46 chronic thromboembolic pulmonary hypertension 10.3 IFNG IL10 TGFB1
47 plummer's disease 10.3 IFNG IL10 TNF
48 osteodysplasty precocious of danks mayne and kozlowski 10.3 IFNG IL10 IL4 TNF
49 neurotic disorder 10.3 IFNG IL10 IL4 TNF
50 acute myeloid leukemia with recurrent genetic anomaly 10.3 IFNG IL10 IL4 TNF

Graphical network of the top 20 diseases related to Leishmaniasis:



Diseases related to Leishmaniasis

Symptoms & Phenotypes for Leishmaniasis

Human phenotypes related to Leishmaniasis:

32 (show all 24)
id Description HPO Frequency HPO Source Accession
1 arthralgia 32 HP:0002829
2 fatigue 32 HP:0012378
3 night sweats 32 HP:0030166
4 splenomegaly 32 HP:0001744
5 hepatomegaly 32 HP:0002240
6 anemia 32 HP:0001903
7 pancytopenia 32 HP:0001876
8 pallor 32 HP:0000980
9 abnormal bleeding 32 HP:0001892
10 weight loss 32 HP:0001824
11 elevated hepatic transaminases 32 HP:0002910
12 thrombocytopenia 32 HP:0001873
13 skin ulcer 32 HP:0200042
14 anorexia 32 HP:0002039
15 papule 32 HP:0200034
16 abnormality of the nose 32 HP:0000366
17 lymphadenopathy 32 HP:0002716
18 abnormality of oral mucosa 32 HP:0011830
19 increased antibody level in blood 32 HP:0010702
20 leukopenia 32 HP:0001882
21 skin plaque 32 HP:0200035
22 hypoalbuminemia 32 HP:0003073
23 episodic fever 32 HP:0001954
24 abnormality of macrophages 32 HP:0004311

UMLS symptoms related to Leishmaniasis:


exanthema, fever, pruritus

GenomeRNAi Phenotypes related to Leishmaniasis according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-100 10.17 IL10
2 Increased shRNA abundance (Z-score > 2) GR00366-A-105 10.17 HSPA4
3 Increased shRNA abundance (Z-score > 2) GR00366-A-108 10.17 HSPA4
4 Increased shRNA abundance (Z-score > 2) GR00366-A-11 10.17 IL13 HSPA4
5 Increased shRNA abundance (Z-score > 2) GR00366-A-113 10.17 IL10 TLR4
6 Increased shRNA abundance (Z-score > 2) GR00366-A-114 10.17 TLR4
7 Increased shRNA abundance (Z-score > 2) GR00366-A-125 10.17 IL10
8 Increased shRNA abundance (Z-score > 2) GR00366-A-128 10.17 IL13 HSPA4 IL10 TLR4
9 Increased shRNA abundance (Z-score > 2) GR00366-A-130 10.17 IL13
10 Increased shRNA abundance (Z-score > 2) GR00366-A-132 10.17 IL10
11 Increased shRNA abundance (Z-score > 2) GR00366-A-152 10.17 IL10
12 Increased shRNA abundance (Z-score > 2) GR00366-A-161 10.17 IL10
13 Increased shRNA abundance (Z-score > 2) GR00366-A-169 10.17 HSPA4 TLR4
14 Increased shRNA abundance (Z-score > 2) GR00366-A-172 10.17 HSPA4
15 Increased shRNA abundance (Z-score > 2) GR00366-A-198 10.17 IL10
16 Increased shRNA abundance (Z-score > 2) GR00366-A-199 10.17 IL13
17 Increased shRNA abundance (Z-score > 2) GR00366-A-210 10.17 IL10
18 Increased shRNA abundance (Z-score > 2) GR00366-A-214 10.17 IL10
19 Increased shRNA abundance (Z-score > 2) GR00366-A-22 10.17 TLR4
20 Increased shRNA abundance (Z-score > 2) GR00366-A-25 10.17 IL10
21 Increased shRNA abundance (Z-score > 2) GR00366-A-39 10.17 IL13
22 Increased shRNA abundance (Z-score > 2) GR00366-A-52 10.17 IL10
23 Increased shRNA abundance (Z-score > 2) GR00366-A-63 10.17 HSPA4
24 Increased shRNA abundance (Z-score > 2) GR00366-A-67 10.17 IL10
25 Increased shRNA abundance (Z-score > 2) GR00366-A-80 10.17 IL10
26 Increased shRNA abundance (Z-score > 2) GR00366-A-82 10.17 IL10
27 Increased shRNA abundance (Z-score > 2) GR00366-A-85 10.17 IL10
28 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.77 TNF IL10 IL1A IL1B NOS2 SRM
29 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.77 IL10 IL1A IL1B NOS2 SRM TGFB1

MGI Mouse Phenotypes related to Leishmaniasis:

44 (show all 17)
id Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.43 TGFB1 TLR2 TLR4 TLR9 TNF IFNG
2 cellular MP:0005384 10.4 IFNG IFNGR1 IL10 IL13 IL4 ITGAM
3 immune system MP:0005387 10.4 TNF IFNG IFNGR1 IL10 IL13 IL1A
4 homeostasis/metabolism MP:0005376 10.39 TGFB1 TLR2 TLR4 TLR9 TNF IFNG
5 digestive/alimentary MP:0005381 10.36 IFNG IFNGR1 IL10 IL13 IL4 IL5
6 cardiovascular system MP:0005385 10.31 IFNG IFNGR1 IL10 IL1A IL1B MPI
7 mortality/aging MP:0010768 10.31 HSPA4 IFNG IFNGR1 IL10 IL13 TNF
8 integument MP:0010771 10.26 IL4 NOS2 TGFB1 TLR2 TLR4 TNF
9 endocrine/exocrine gland MP:0005379 10.24 HSPA4 IFNG IFNGR1 IL10 IL13 IL4
10 liver/biliary system MP:0005370 10.16 IFNG IFNGR1 IL10 IL4 IL5 NOS2
11 neoplasm MP:0002006 10.15 SLC11A1 TGFB1 TLR2 TLR4 TNF IFNG
12 nervous system MP:0003631 10.13 HSPA4 IFNG IFNGR1 IL10 IL1B IL4
13 muscle MP:0005369 10.01 IFNG IL10 IL13 NOS2 TGFB1 TLR2
14 reproductive system MP:0005389 9.9 HSPA4 IFNG IFNGR1 IL10 IL13 IL4
15 renal/urinary system MP:0005367 9.86 IFNGR1 IL4 NOS2 TGFB1 TLR2 TLR4
16 respiratory system MP:0005388 9.65 IFNG IL10 IL13 TLR2 IL4 TLR4
17 skeleton MP:0005390 9.4 IFNG IFNGR1 IL10 IL13 IL1B IL4

Drugs & Therapeutics for Leishmaniasis

Drugs for Leishmaniasis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 144)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
chloroquine Approved, Vet_approved Phase 4 54-05-7 2719
2
Primaquine Approved Phase 4 90-34-6 4908
3
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 22916-47-8 4189
4
Miltefosine Approved Phase 4,Phase 3,Phase 2,Phase 1 58066-85-6 3600
5
Amphotericin B Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 1397-89-3 14956 5280965
6
deoxycholic acid Approved Phase 4,Phase 3 83-44-3 222528
7
Paromomycin Approved, Investigational Phase 4,Phase 3,Phase 2,Early Phase 1 1263-89-4, 7542-37-2 165580
8
Lidocaine Approved, Vet_approved Phase 4,Phase 2,Phase 3 137-58-6 3676
9 Analgesics Phase 4,Phase 2,Phase 3
10 Analgesics, Non-Narcotic Phase 4,Phase 2,Phase 3
11 Anthelmintics Phase 4,Phase 3,Phase 2,Phase 1
12 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
13 Anti-Inflammatory Agents Phase 4,Phase 2,Phase 3
14 Anti-Inflammatory Agents, Non-Steroidal Phase 4,Phase 2,Phase 3
15 Antimalarials Phase 4
16 Antiparasitic Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
17 Antiprotozoal Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
18 Antirheumatic Agents Phase 4,Phase 2,Phase 3
19 Chloroquine diphosphate Phase 4 50-63-5
20 Peripheral Nervous System Agents Phase 4,Phase 2,Phase 3
21 meglumine antimoniate Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
22 Antifungal Agents Phase 4,Phase 3,Phase 2,Phase 1
23 Antimony Sodium Gluconate Phase 4,Phase 3,Phase 2,Phase 1
24 Amphotericin B, deoxycholate drug combination Phase 4,Phase 3
25 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
26 Cholagogues and Choleretics Phase 4,Phase 3
27 Gastrointestinal Agents Phase 4,Phase 3,Phase 1
28 Liposomal amphotericin B Phase 4,Phase 3,Phase 2,Phase 1
29 Anesthetics Phase 4
30
Ethanol Approved Phase 2, Phase 3 64-17-5 702
31
Petrolatum Approved Phase 2, Phase 3 8009-03-8
32
Salicylic acid Approved, Vet_approved Phase 2, Phase 3 69-72-7 338
33
Pentoxifylline Approved, Investigational Phase 2, Phase 3 6493-05-6 4740
34
Pentamidine Approved Phase 3,Phase 2 100-33-4 4735
35
Imiquimod Approved, Investigational Phase 3,Phase 2 99011-02-6 57469
36
Nitric Oxide Approved Phase 3 10102-43-9 145068
37
Azithromycin Approved Phase 2, Phase 3 83905-01-5 55185 53477736 447043
38
Fluconazole Approved Phase 3 86386-73-4 3365
39
Pyruvate Approved, Nutraceutical Phase 2, Phase 3
40
Calcitriol Approved, Nutraceutical Phase 2, Phase 3 32222-06-3 134070 5280453
41
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2, Phase 3 59-30-3 6037
42
Niacin Approved, Investigational, Nutraceutical Phase 2, Phase 3 59-67-6 938
43
Nicotinamide Approved, Nutraceutical Phase 2, Phase 3 98-92-0 936
44
Vitamin E Approved, Nutraceutical, Vet_approved Phase 3 59-02-9 14985
45 Cyclooxygenase Inhibitors Phase 2, Phase 3
46 Dermatologic Agents Phase 2, Phase 3
47 Keratolytic Agents Phase 2, Phase 3
48 Pharmaceutical Solutions Phase 2, Phase 3
49 Salicylates Phase 2, Phase 3
50 Antioxidants Phase 2, Phase 3

Interventional clinical trials:

(show top 50) (show all 138)
id Name Status NCT ID Phase
1 Estimating the Risk of Plasmodium Vivax Relapses in Afghanistan Unknown status NCT01178021 Phase 4
2 Safety and Efficacy of Low-Dose Pentavalent Antimony for Treatment of Cutaneous Leishmaniasis Completed NCT00317980 Phase 4
3 Amphotericin B to Treat Visceral Leishmaniasis in Brazilian Children Completed NCT01032187 Phase 4
4 Low-dose Pentavalent Antimony Treatment of Cutaneous Leishmaniasis in Old Age Patients Completed NCT00818818 Phase 4
5 A Study to Explore Association of Treatment Regimens for Visceral Leishmaniasis, Host Immunological, Genetical and Nutrition Factors With Post-kala-azar Dermal Leishmaniasis (PKDL) Completed NCT01975051 Phase 4
6 Expand Access/Assess Safety and Efficacy of Paromomycin IM Injection for the Treatment of Visceral Leishmaniasis Completed NCT00604955 Phase 4
7 Efficacy of Radio-frequency Induced Heat (RFH)Therapy in Treatment of Cutaneous Leishmaniasis in India Completed NCT01661296 Phase 4
8 Pharmacokinetics of Miltefosine in Children and Adults Completed NCT01462500 Phase 4
9 Single Dose Liposomal Amphotericin B for Visceral Leishmaniasis Not yet recruiting NCT01566552 Phase 4
10 Efficacy and Safety Study of Drugs for Treatment of Visceral Leishmaniasis in Brazil Terminated NCT01310738 Phase 4
11 Oral Miltefosine for the Treatment of Pediatric Cutaneous Leishmaniasis in Colombia Unknown status NCT00487253 Phase 3
12 Pyruvic Acid Versus Salicylic Acid Preparation in Treatment of Plantar Warts Unknown status NCT02151630 Phase 2, Phase 3
13 An Open Lable Randomised Study to Assess the Safety and Efficacy of Short Course Paromomycin in Visceral Leishmaniasis Completed NCT00629031 Phase 3
14 Antimony Plus Pentoxifylline in Cutaneous Leishmaniasis Completed NCT01381055 Phase 2, Phase 3
15 To Study the Effect Of Single Infusions Of Amphotericin B Lipid Preparations in Treatment of Patients Of Kala Azar Completed NCT00876824 Phase 3
16 Single Infusion of Liposomal Amphotericin B in Indian Visceral Leishmaniasis Completed NCT00628719 Phase 3
17 Liposomal Amphotericin in Disseminated Leishmaniasis Completed NCT02025491 Phase 3
18 Add-on Study of Pentoxifylline in Cutaneous Leishmaniasis Completed NCT01464242 Phase 2, Phase 3
19 Phase 3 Study to Evaluate WR 279,396 vs. Paromomycin Alone to Treat Cutaneous Leishmaniasis (in Tunisia) Completed NCT00606580 Phase 3
20 Safety and Efficacy Study of Paromomycin to Treat Visceral Leishmaniasis Completed NCT00216346 Phase 3
21 Efficacy and Safety of Miltefosine or Thermotherapy for Cutaneous Leishmaniasis in Colombia. Completed NCT00471705 Phase 3
22 Safety and Efficacy Study to Evaluate Different Combination Treatment Regimens for Visceral Leishmaniasis Completed NCT00696969 Phase 3
23 Prophylaxis of Visceral Leishmaniasis Relapses in HIV Co-infected Patients With Pentamidine: a Cohort Study Completed NCT01360762 Phase 3
24 Combination Therapy in Indian Visceral Leishmaniasis Completed NCT00523965 Phase 3
25 Imiquimod Plus Antimony Immunochemotherapy for Cutaneous Leishmaniasis Completed NCT00257530 Phase 3
26 Efficacy/Safety of Sodium Stibogluconate (SSG) Versus Paromomycin (PM) and SSG/PM Combination to Treat V Leishmaniasis Completed NCT00255567 Phase 3
27 Phase 3 Study of Walter Reed (WR) 279,396 and Paromomycin Alone for the Treatment of Cutaneous Leishmaniasis in Panama Completed NCT01790659 Phase 3
28 Efficacy Trial on Oral Miltefosine in Comparison With Glucantime in the Treatment of ACL Caused by L. Tropica Completed NCT00351520 Phase 3
29 Replacement of Insecticides to Control Visceral Leishmaniasis (VL) Completed NCT01644682 Phase 3
30 Rationale for New Topical Anthroponotic Cutaneous Leishmaniasis (ACL) Treatment in Kabul Completed NCT00947362 Phase 2, Phase 3
31 Phase III, Study of Three Short Course Combo (Ambisome®, Miltefosine, Paromomycin) Compared With AmBisome for the Treatment of VL in Bangladesh Completed NCT01122771 Phase 3
32 Safety/Efficacy Trial of Killed Leishmania Vaccine in Volunteers With no Response to Leishmanin Completed NCT00429715 Phase 2, Phase 3
33 Safety/Efficacy Trial of Killed Leishmania Vaccine in Volunteers With Positive Response to Leishmanin (LST>0) Completed NCT00429780 Phase 2, Phase 3
34 Clinical Trial for the Treatment of Diabetic Foot Ulcers Using a Nitric Oxide Releasing Patch: PATHON Completed NCT00428727 Phase 3
35 Nicotinamide in the Treatment of Psoriasis Completed NCT01763424 Phase 2, Phase 3
36 Low Antimonial Dosage in American Mucosal Leishmaniasis Recruiting NCT01301937 Phase 2, Phase 3
37 Miltefosine for Children With PKDL Recruiting NCT02193022 Phase 3
38 Comparison of Standard and Alternative Antimonial Dosage in Patients With American Cutaneous Leishmaniasis Active, not recruiting NCT01301924 Phase 2, Phase 3
39 Efficacy Trial of Ambisome Given Alone and Ambisome Given in Combination With Miltefosine for the Treatment of VL HIV Positive Ethiopian Patients. Active, not recruiting NCT02011958 Phase 3
40 Miltefosine and GM-CSF in Cutaneous Leishmaniasis Not yet recruiting NCT03023111 Phase 3
41 Miltefosine/Paromomycin Phase III Trial for Treatment of Primary Visceral Leishmaniasis (VL) Patients in Eastern Africa Not yet recruiting NCT03129646 Phase 3
42 Topical Paromomycin for Cutaneous Leishmaniasis in Bolivia Not yet recruiting NCT03096457 Phase 2, Phase 3
43 Safety and Efficacy of Azithromycin to Treat Cutaneous Leishmaniasis Terminated NCT00682656 Phase 2, Phase 3
44 High Dose Fluconazole in Cutaneous Leishmaniasis in Bahia and Manaus Terminated NCT01953744 Phase 3
45 Controlled Nitric Oxide Releasing Patch Versus Meglumine Antimoniate in the Treatment of Cutaneous Leishmaniasis Terminated NCT00317629 Phase 3
46 Study of the Efficacy of Daylight Activated Photodynamic Therapy in the Treatment of Cutaneous Leishmaniasis Unknown status NCT00840359 Phase 2
47 Short Course of Miltefosine and Antimony to Treat Cutaneous Leishmaniasis in Bolivia Unknown status NCT00537953 Phase 2
48 Sodium Stibogluconate Treatment of Leishmaniasis Completed NCT00662012 Phase 2
49 Use of Sodium Stibogluconate as a Treatment for Leishmaniasis Completed NCT00657618 Phase 1, Phase 2
50 Topical Treatment of Recalcitrant Ulcerative Old World Leishmaniasis With WR 279,396 Completed NCT00657917 Phase 2

Search NIH Clinical Center for Leishmaniasis

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cochrane evidence based reviews: leishmaniasis

Genetic Tests for Leishmaniasis

Anatomical Context for Leishmaniasis

MalaCards organs/tissues related to Leishmaniasis:

39
Skin, Liver, Spleen, Bone, Bone Marrow, T Cells, Testes

Publications for Leishmaniasis

Articles related to Leishmaniasis:

(show top 50) (show all 1951)
id Title Authors Year
1
Diagnosis of Mediterranean visceral leishmaniasis by detection of Leishmania-related antigen in urine and oral fluid samples. ( 28017861 )
2017
2
Alterations in Evoked Otoacoustic Emissions by the Use of Meglumine Antimoniate in American Tegumentary Leishmaniasis Patients. ( 28045920 )
2017
3
Immunization with Leishmania donovani protein disulfide isomerase DNA construct induces Th1 and Th17 dependent immune response and protection against experimental visceral leishmaniasis in Balb/c mice. ( 28064069 )
2017
4
Leishmania tropica: Combined debulking and imiquimod for the treatment of nonresponsive cutaneous leishmaniasis. ( 27986151 )
2017
5
Managing two decades of visceral leishmaniasis and HIV co-infection: a case report that illustrates the urgent research needs in the field. ( 28063460 )
2017
6
SLC11A1 polymorphisms and host susceptibility to cutaneous leishmaniasis in Pakistan. ( 28061874 )
2017
7
First description of Leishmania (Viannia) infection in Evandromyia saulensis, Pressatia sp. and Trichophoromyia auraensis (Psychodidae: Phlebotominae) in a transmission area of cutaneous leishmaniasis in Acre state, Amazon Basin, Brazil. ( 28076470 )
2017
8
Safety and Effectiveness of Sodium Stibogluconate and Paromomycin Combination for the Treatment of Visceral Leishmaniasis in Eastern Africa: Results from a Pharmacovigilance Programme. ( 28066878 )
2017
9
Aspects on the Ecology of Phlebotomine Sand Flies (Diptera: Psychodidae) From GuaraA-, State of Tocantins, Brazil, Endemic Area for American Cutaneous Leishmaniasis. ( 28082651 )
2017
10
Comparative genomics of canine-isolated Leishmania (Leishmania) amazonensis from an endemic focus of visceral leishmaniasis in Governador Valadares, southeastern Brazil. ( 28091623 )
2017
11
Adenosine generated by ectonucleotidases modulates the host immune system during visceral leishmaniasis. ( 28082236 )
2017
12
Scoring clinical signs can help diagnose canine visceral leishmaniasis in a highly endemic area in Brazil. ( 28076469 )
2017
13
Leishmanicidal and Trypanocidal Activity of Metal Complexes with 1,2,4-Triazolo[1,5-a]pyrimidines: Insights on their Therapeutic Potential against Leishmaniasis and Chagas Disease. ( 28521698 )
2017
14
The pulsed dye laser is more effective and rapidly acting than intralesional meglumine antimoniate therapy for cutaneous leishmaniasis. ( 28043177 )
2017
15
Reprint of "Spatial modeling of Cutaneous Leishmaniasis in Iran from 1983 to 2013". ( 27914666 )
2017
16
Sporothrix schenckii Sensu Lato identification in fragments of skin lesion cultured in NNN medium for differential diagnosis of cutaneous leishmaniasis. ( 27914747 )
2017
17
The new situation of cutaneous leishmaniasis after Syrian civil war in Gaziantep city, Southeastern region of Turkey. ( 27983970 )
2017
18
A Comparison between the Effects of Glucantime, Topical Trichloroacetic Acid 50% plus Glucantime, and Fractional Carbon Dioxide Laser plus Glucantime on Cutaneous Leishmaniasis Lesions. ( 27148363 )
2016
19
Effective treatment of cutaneous leishmaniasis caused by Leishmania tropica with topical photodynamic therapy. ( 27509427 )
2016
20
The anti-tubercular drug delamanid as a potential oral treatment for visceral leishmaniasis. ( 27215734 )
2016
21
NOD2-RIP2-mediated signalling contributes to shape adaptive immunity in visceral leishmaniasis. ( 27651416 )
2016
22
Spatial Analyses of the Relation between Rodent's Active Burrows and Incidence of Zoonotic Cutaneous Leishmaniasis in Golestan Province, Northeastern of Iran. ( 28032109 )
2016
23
Molecular Epidemiological Survey of Cutaneous Leishmaniasis in Two Highly Endemic Metropolises of Iran, Application of FTA Cards for DNA Extraction From Giemsa-Stained Slides. ( 27127596 )
2016
24
Xenodiagnosis on dogs with visceral leishmaniasis: Canine and sand fly aspects related to the parasite transmission. ( 27198788 )
2016
25
A nanotechnology based new approach for chemotherapy of Cutaneous Leishmaniasis: TIO2@AG nanoparticles - Nigella sativa oil combinations. ( 27109311 )
2016
26
Epidemiologic profile of oriental sore caused by Leishmania parasites in a new endemic focus of cutaneous leishmaniasis, southern Iran. ( 27605840 )
2016
27
Pharmacovigilance of Miltefosine in Treatment of Visceral Leishmaniasis in Endemic Areas of Bihar, India. ( 27645786 )
2016
28
IL-18 gene polymorphism in patients with visceral leishmaniasis in East Azarbaijan, Iran. ( 27605823 )
2016
29
Topical Simvastatin as Host-Directed Therapy against Severity of Cutaneous Leishmaniasis in Mice. ( 27632901 )
2016
30
Faunal Distribution and Seasonal Bio-Ecology of Naturally Infected Sand Flies in a New Endemic Zoonotic Cutaneous Leishmaniasis Focus of Southern Iran. ( 28032108 )
2016
31
Correlation of Genetic Heterogeneity with Cytopathological and Epidemiological Findings of Leishmania major Isolated from Cutaneous Leishmaniasis in Southern Iran. ( 27215312 )
2016
32
The quest for canine leishmaniasis in Romania: the presence of an autochthonous focus with subclinical infections in an area where disease occurred. ( 27209427 )
2016
33
Cutaneous Leishmaniasis: The Truth about the 'Flesh-Eating Disease' in Syria. ( 27105932 )
2016
34
Pediatric Dermatology Photoquiz: Refractory Purulent Paronychia in a Young Girl. Paronychial cutaneous leishmaniasis. ( 26758096 )
2016
35
Frequency of Cutaneous Leishmaniasis and Species Identification in Suspected Individuals from Golestan Province, Northern Iran in 2014. ( 27957442 )
2016
36
Supplementation of host response by targeting nitric oxide to the macrophage cytosol is efficacious in the hamster model of visceral leishmaniasis and adds to efficacy of amphotericin B. ( 27183429 )
2016
37
Intralesional Versus Oral Chloroquine in Cutaneous Leishmaniasis: Comparison of Outcome, Duration of Treatment and Total Dose of Drug. ( 27097693 )
2016
38
Therapeutic Effect of Scrophularia striata Ethanolic Extract against Localized Cutaneous Leishmaniasis Caused by Leishmania major (MRHO/IR/75/ER). ( 27957441 )
2016
39
Canine Visceral Leishmaniasis in Wild Canines (Fox, Jackal, and Wolf) in Northeastern Iran Using Parasitological, Serological, and Molecular Methods. ( 28032106 )
2016
40
Mycobacterium indicus pranii (Mw)-mediated protection against visceral leishmaniasis by reciprocal regulation of host dual-specificity phosphatases. ( 28013190 )
2016
41
Amiodarone triggers induction of apoptosis in cutaneous leishmaniasis agents. ( 27553974 )
2016
42
Disseminated cutaneous leishmaniasis: ulcerovegetative and ulcero-crusted lesions. ( 28012931 )
2016
43
Comparative B-mode and Doppler renal ultrasonography with histopathological findings in dogs positive for canine visceral leishmaniasis. ( 27194210 )
2016
44
Hair parasite load as a new biomarker for monitoring treatment response in canine leishmaniasis. ( 27198771 )
2016
45
Correction: Down-Regulation of TLR and JAK/STAT Pathway Genes Is Associated with Diffuse Cutaneous Leishmaniasis: A Gene Expression Analysis in NK Cells from Patients Infected with Leishmania Mexicana. ( 27096541 )
2016
46
Insulin-like growth factor-I serum levels and their biological effects on Leishmania isolates from different clinical forms of American tegumentary leishmaniasis. ( 27286813 )
2016
47
Identification of Leishmania Species Isolated from Human Cutaneous Leishmaniasis in Mehran, Western Iran Using Nested PCR. ( 27095970 )
2016
48
Gene deleted live attenuated Leishmania vaccine candidates against visceral leishmaniasis elicit pro-inflammatory cytokines response in human PBMCs. ( 27624408 )
2016
49
Successful Treatment of Cutaneous Leishmaniasis with Topical Paramomycin in a Child After Treatment Failure with Systemic Fluconazole. ( 27549634 )
2016
50
Panniculitis is a common unrecognized histopathological feature of cutaneous leishmaniasis. ( 26960628 )
2016

Variations for Leishmaniasis

Expression for Leishmaniasis

Search GEO for disease gene expression data for Leishmaniasis.

Pathways for Leishmaniasis

Pathways related to Leishmaniasis according to GeneCards Suite gene sharing:

(show top 50) (show all 84)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
14.19 IFNG IFNGR1 IL10 IL13 IL1A IL1B
2
Show member pathways
13.81 IFNG IFNGR1 IL10 IL13 IL1A IL1B
3
Show member pathways
13.69 IFNG IFNGR1 IL10 IL13 IL1A IL1B
4
Show member pathways
13.59 IL10 IL13 IL1A IL1B IL4 IL5
5
Show member pathways
13.54 IFNG IFNGR1 IL10 IL13 IL1A IL1B
6
Show member pathways
13.41 IL10 IL13 IL1A IL1B IL4 IL5
7
Show member pathways
13.35 IFNG IFNGR1 IL1A IL1B IL4 TLR2
8
Show member pathways
13.11 IL1A IL1B NOS2 TLR2 TLR4 TLR9
9
Show member pathways
13.11 IFNG IFNGR1 IL10 IL1B NOS2 TGFB1
10
Show member pathways
13.06 HSPA4 IFNG IL10 IL13 IL1A IL1B
11
Show member pathways
13 IFNG IFNGR1 IL13 IL1A IL1B IL4
12
Show member pathways
12.87 IL1A IL1B TGFB1 TLR2 TLR4 TLR9
13
Show member pathways
12.75 IFNG IFNGR1 IL1A IL1B TNF
14
Show member pathways
12.74 IL1A IL1B TLR2 TLR4 TLR9 TNF
15 12.74 IFNG IL10 IL1B IL4 TLR2 TLR9
16
Show member pathways
12.71 IFNG IFNGR1 IL10 IL4 TNF
17
Show member pathways
12.68 IFNG IL10 IL1B NOS2 TNF
18
Show member pathways
12.68 IFNG IFNGR1 IL10 IL13 IL1A IL1B
19
Show member pathways
12.65 IFNG IL10 IL1A IL1B IL4 IL5
20
Show member pathways
12.55 IFNG IL13 IL1B IL4 IL5 TLR2
21
Show member pathways
12.49 IFNG IFNGR1 IL1A IL1B NOS2 TLR4
22
Show member pathways
12.41 IFNG IFNGR1 IL10 IL13 IL4 IL5
23
Show member pathways
12.4 IL1A TLR2 TLR4 TLR9 TNF
24 12.4 IFNG IFNGR1 NOS2 TGFB1 TLR2 TLR4
25
Show member pathways
12.39 IFNG IL1B IL4 TNF
26 12.37 TGFB1 TLR2 TLR4 TNF
27
Show member pathways
12.37 IFNG IFNGR1 IL1B IL4 NOS2 TLR2
28
Show member pathways
12.37 IFNG IFNGR1 IL10 IL1A IL1B IL4
29
Show member pathways
12.35 IFNG IL10 IL13 IL1A IL1B IL4
30 12.33 IL10 IL13 IL1A IL1B TNF
31 12.29 IFNG IFNGR1 IL10 IL1A IL1B ITGAM
32 12.27 IFNG IFNGR1 IL1A IL1B TGFB1 TNF
33
Show member pathways
12.26 IL13 IL1A IL1B IL5 TLR2 TLR4
34 12.23 IFNG IL10 IL4 IL5 ITGAM TNF
35 12.21 IFNG IL1A IL1B IL4 NOS2 TGFB1
36 12.19 IFNG IL1A IL1B TNF
37 12.17 IL10 IL13 IL1A IL1B IL4 ITGAM
38
Show member pathways
12.15 IFNG IL1B IL4 TGFB1 TLR2 TLR4
39 12.14 IL1A IL1B IL4 IL5 ITGAM TNF
40
Show member pathways
12.09 IFNG IL1B IL4 NOS2
41
Show member pathways
12.09 IFNG IFNGR1 IL10 IL1B TGFB1 TLR2
42 12.08 IFNG IL1A IL1B TGFB1 TLR2 TLR4
43 12.07 IFNG IFNGR1 IL1A IL1B NOS2 TLR4
44 12.07 IFNG IL10 IL1B ITGAM NOS2 TGFB1
45 12.06 IFNG IL1A IL1B TGFB1
46 12.03 IL1A IL1B TGFB1 TNF
47 12.03 IFNG IFNGR1 NOS2 TLR4
48 11.99 IFNG IL10 IL1B ITGAM TGFB1 TLR9
49 11.98 IL10 IL1A IL1B ITGAM NOS2 TLR4
50 11.98 IFNG IL10 IL13 IL1B IL4 IL5

GO Terms for Leishmaniasis

Cellular components related to Leishmaniasis according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.85 IFNG IL10 IL13 IL1A IL1B IL4
2 extracellular space GO:0005615 9.36 IFNG IL10 IL13 IL1A IL1B IL4
3 external side of plasma membrane GO:0009897 9.35 IFNG IL13 IL4 TLR4 TNF

Biological processes related to Leishmaniasis according to GeneCards Suite gene sharing:

(show top 50) (show all 97)
id Name GO ID Score Top Affiliating Genes
1 cellular response to mechanical stimulus GO:0071260 9.99 IL13 IL1B TGFB1 TLR4
2 regulation of insulin secretion GO:0050796 9.97 IFNG IL1B NOS2 TNF
3 positive regulation of JNK cascade GO:0046330 9.97 IL1B TLR4 TLR9 TNF
4 cellular response to organic cyclic compound GO:0071407 9.95 IL1B TGFB1 TNF
5 positive regulation of T cell proliferation GO:0042102 9.94 IFNG IL1B IL4
6 defense response to Gram-negative bacterium GO:0050829 9.94 NOS2 SLC11A1 TLR4 TLR9
7 positive regulation of inflammatory response GO:0050729 9.93 TLR2 TLR4 TLR9
8 positive regulation of tumor necrosis factor production GO:0032760 9.93 IFNG TLR2 TLR4 TLR9
9 positive regulation of cell division GO:0051781 9.92 IL1A IL1B TGFB1
10 toll-like receptor signaling pathway GO:0002224 9.92 TLR2 TLR4 TLR9
11 extrinsic apoptotic signaling pathway GO:0097191 9.92 IFNG TGFB1 TNF
12 positive regulation of interferon-gamma production GO:0032729 9.92 IL1B SLC11A1 TLR4 TNF
13 positive regulation of nitric oxide biosynthetic process GO:0045429 9.91 IFNG IL1B TLR4 TNF
14 positive regulation of B cell proliferation GO:0030890 9.91 IL13 IL4 IL5 TLR4
15 positive regulation of gene expression GO:0010628 9.91 IFNG IL1A IL1B SLC11A1 TGFB1 TLR2
16 positive regulation of protein secretion GO:0050714 9.9 IL13 IL1A TGFB1
17 negative regulation of extrinsic apoptotic signaling pathway in absence of ligand GO:2001240 9.9 IL1A IL1B TNF
18 response to bacterium GO:0009617 9.9 NOS2 SLC11A1 TLR4
19 protein kinase B signaling GO:0043491 9.9 IL1B TGFB1 TNF
20 MyD88-dependent toll-like receptor signaling pathway GO:0002755 9.9 TLR2 TLR4 TLR9
21 extrinsic apoptotic signaling pathway in absence of ligand GO:0097192 9.89 IL1A IL1B IL4
22 positive regulation of phagocytosis GO:0050766 9.89 IL1B SLC11A1 TNF
23 positive regulation of cytokine secretion GO:0050715 9.89 IL10 IL1A TNF
24 negative regulation of interleukin-6 production GO:0032715 9.89 IL10 TLR4 TLR9 TNF
25 negative regulation of endothelial cell apoptotic process GO:2000352 9.88 IL10 IL13 IL4
26 protein import into nucleus, translocation GO:0000060 9.88 IFNG TGFB1 TNF
27 negative regulation of mitotic cell cycle GO:0045930 9.88 IL10 TGFB1 TNF
28 positive regulation of vascular endothelial growth factor production GO:0010575 9.88 IL1A IL1B TGFB1
29 positive regulation of interleukin-12 production GO:0032735 9.88 IFNG TLR2 TLR4 TLR9
30 positive regulation of interferon-beta production GO:0032728 9.87 TLR2 TLR4 TLR9
31 positive regulation of protein complex assembly GO:0031334 9.87 IFNG TGFB1 TNF
32 positive regulation of interleukin-10 production GO:0032733 9.87 IL4 TLR2 TLR4 TLR9
33 defense response to protozoan GO:0042832 9.86 IFNG IL10 IL4 SLC11A1
34 negative regulation of growth of symbiont in host GO:0044130 9.85 IFNG IL10 TNF
35 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.85 IFNG IL1B TNF
36 positive regulation of nitric-oxide synthase biosynthetic process GO:0051770 9.84 TLR2 TLR4 TLR9
37 microglial cell activation GO:0001774 9.84 IL13 IL4 TLR2
38 response to molecule of bacterial origin GO:0002237 9.83 IL10 TLR2 TLR9
39 I-kappaB phosphorylation GO:0007252 9.83 TLR2 TLR4 TLR9
40 positive regulation of chemokine production GO:0032722 9.83 TLR2 TLR4 TLR9 TNF
41 lipopolysaccharide-mediated signaling pathway GO:0031663 9.83 IL1B TGFB1 TLR2 TLR4 TNF
42 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.82 IL10 IL1B TNF
43 regulation of cytokine secretion GO:0050707 9.82 TLR2 TLR4 TLR9
44 negative regulation of interleukin-17 production GO:0032700 9.81 IFNG TGFB1 TLR4
45 positive regulation of podosome assembly GO:0071803 9.78 IL5 TNF
46 positive regulation of chemokine biosynthetic process GO:0045080 9.78 IFNG IL1B IL4 TNF
47 positive regulation of interleukin-2 biosynthetic process GO:0045086 9.77 IL1A IL1B
48 macrophage activation GO:0042116 9.77 SLC11A1 TLR4
49 positive regulation of isotype switching to IgG isotypes GO:0048304 9.77 IFNG IL4
50 positive regulation of mast cell degranulation GO:0043306 9.77 IL13 IL4

Molecular functions related to Leishmaniasis according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 growth factor activity GO:0008083 9.56 IL10 IL4 IL5 TGFB1
2 cytokine activity GO:0005125 9.28 IFNG IL10 IL13 IL1A IL1B IL4
3 lipopolysaccharide receptor activity GO:0001875 9.16 TLR2 TLR4
4 interleukin-1 receptor binding GO:0005149 9.13 IL1A IL1B TLR9

Sources for Leishmaniasis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....